Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Bayer |
---|---|
Information provided by: | Bayer |
ClinicalTrials.gov Identifier: | NCT00185276 |
The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Magnevist® (the study drug) used for MRI of the infrarenal aorta and peripheral arteries. The results will be compared to the results of MRI taken without Magnevist®, and with the results of your X-ray angiography.
Condition | Intervention | Phase |
---|---|---|
Peripheral Vascular Disease |
Drug: Magnevist (Gadopentetate dimeglumine) |
Phase III |
Study Type: | Interventional |
Study Design: | Diagnostic, Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Randomized, Multi-Center Open Label Study of the Safety (Open-Label) and Efficacy (Open-Label & Blinded Reader) of Magnevist® Injection-Enhanced Magnetic Resonance Arteriography (MRA) at Two Dose Levels and 2-Dimensional-Time-of-Flight (2D-TOF) MRA in Patients Undergoing MRA of the Infrarenal Aorta and Peripheral Arteries With Intra-Arterial Digital Subtraction Arteriography (i.a. DSA) as Standard of Reference |
Enrollment: | 369 |
Study Start Date: | March 2003 |
Study Completion Date: | August 2004 |
Arms | Assigned Interventions |
---|---|
Arm 1: Experimental
N/A
|
Drug: Magnevist (Gadopentetate dimeglumine)
Single intravenous injection on the study day: lower dose corresponding approximately 0.1 mmol/kg body weight
|
Arm 2: Experimental
N/A
|
Drug: Magnevist (Gadopentetate dimeglumine)
Single intravenous injection on the study day: higher dose corresponding approximately 0.2 - 0.3 mmol/kg body weight
|
This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | ( Bayer Healthcare Pharmaceuticals Inc., Therapeutic Area Head ) |
Study ID Numbers: | 91208, 306781 |
Study First Received: | September 10, 2005 |
Last Updated: | April 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00185276 |
Health Authority: | United States: Food and Drug Administration; Argentina: Ministry of Health; United States: Food and Drug Administration |
Structural abnormalities of the infrarenal aorta and peripheral arteries Peripheral vascular disease |
Peripheral Vascular Diseases Vascular Diseases Congenital Abnormalities |
Cardiovascular Diseases |